Low-dose irradiation for reversing immunotherapy resistance: how to translate?
Adaptive Immunity
Drug Therapy, Combination
Immunity, Innate
Immunotherapy
Radiotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
09
06
2022
entrez:
14
7
2022
pubmed:
15
7
2022
medline:
19
7
2022
Statut:
ppublish
Résumé
The use of low-dose irradiation (LDI) for mobilizing innate and adaptive immunity is gaining interest among the scientific community. Recent evidence suggests that LDI can reprogramme the tumor microenvironment, induce inflammation and turn cold tumors susceptible to immunecheckpoint blockade therapy. Translating immuno-radiation preclinical findings in the clinic is more challenging than expected. We propose therapeutic strategies for combining LDI with immunotherapy, and emphasize the importance of pursuing clinical research to determine optimal radiation dosage, fractionation, volumes, and sequencing to stimulate immune-mediated tumor responses.
Identifiants
pubmed: 35835490
pii: jitc-2022-004939
doi: 10.1136/jitc-2022-004939
pmc: PMC9289035
pii:
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Radiother Oncol. 2021 Sep;162:60-67
pubmed: 34237343
Cancer Discov. 2022 Jan;12(1):108-133
pubmed: 34479871
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Cancer Immunol Res. 2019 Dec;7(12):1903-1909
pubmed: 31658994
Clin Transl Radiat Oncol. 2019 Oct 22;20:30-38
pubmed: 31768424
Nat Med. 2021 Jan;27(1):152-164
pubmed: 33398162
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Trends Immunol. 2022 Mar;43(3):173-179
pubmed: 35105519
Clin Cancer Res. 2020 Dec 15;26(24):6437-6444
pubmed: 33028595
Sci Transl Med. 2021 Jul 14;13(602):
pubmed: 34261797
Cancer Immunol Res. 2017 Nov;5(11):992-1004
pubmed: 28970196
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33106386
Sci Immunol. 2021 Apr 9;6(58):
pubmed: 33837124
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151
pubmed: 30227198
Lancet Oncol. 2021 Jun;22(6):824-835
pubmed: 34015311
J Clin Oncol. 2021 Jan 1;39(1):30-37
pubmed: 32822275
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1099-107
pubmed: 25442041
BMC Genomics. 2020 Jan 2;21(1):2
pubmed: 31898484
PLoS One. 2016 Jun 09;11(6):e0157164
pubmed: 27281029
Clin Cancer Res. 2021 May 1;27(9):2470-2480
pubmed: 33568343
CA Cancer J Clin. 2017 Jan;67(1):65-85
pubmed: 27570942
Lancet Oncol. 2022 Feb;23(2):279-291
pubmed: 35033226